CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187

Available online at: http://www.iajps.com Research Article

EVALUATION OF THE POST-APPROVAL CHANGE REQUIREMENTS FOR PHARMACEUTICALS IN INDIA

N. Vasavi*[1], Wajid Ali.MD[1]

[1]Department of Regulatory Affairs, Jayamukhi Institute of Pharmaceutical Sciences, Narsampet, Warangal, Telangana-506132

Abstract:

Post-approval change (PAC) requirements play a critical role in maintaining the safety, efficacy, and quality of pharmaceutical products throughout their lifecycle. In India, these requirements are governed by the Central Drugs Standard Control Organization (CDSCO) and guided by Schedule M, the Drugs and Cosmetics Rules, and emerging harmonization efforts with global regulatory frameworks such as ICH Q12. This study evaluates the regulatory landscape for post-approval changes in India, focusing on the categorization, documentation, and approval pathways for variations in manufacturing processes, formulation, packaging, and analytical methods. The analysis highlights challenges in regulatory timelines, data expectations, and the need for risk-based approaches to streamline change management and ensure continued compliance.

Keywords: *Post-approval changes, CDSCO, Schedule M, regulatory compliance, variation filing, lifecycle management, pharmaceuticals, ICH Q12, India.*

Corresponding author:

N. Vasavi,

Department of Regulatory Affairs, Jayamukhi Institute of Pharmaceutical Sciences, Narsampet, Warangal, Telangana.

Mobile:

Email Id: *harika.vennam02@gmail.com*

QR CODE

Please cite this article in press N Vasavi et al., Evaluation of the post-approval change requirements for pharmaceuticals in India. Indo Am. J. P. Sci, 2026; 13(08).

INTRODUCTION:

1.1 Background of Post-Approval Changes

The pharmaceutical industry operates within one of the most stringently regulated sectors in the world, primarily due to the direct impact that medicines have on public health and patient safety. Once a medicinal product is approved by a regulatory authority, its development journey does not end; rather, it transitions into a phase of continuous monitoring, control, and optimization known as the *post-approval lifecycle*. During this stage, manufacturers often need to implement changes in various aspects of the product, such as its manufacturing process, formulation composition, packaging, testing methods, or labeling.[1] These modifications are referred to as **post-approval changes (PACs)**.

Post-approval changes are essential for multiple reasons: to improve manufacturing efficiency, incorporate technological advancements, address supply chain constraints, and ensure consistent product quality in response to regulatory updates or safety findings. Regulatory authorities across the globe, including the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO) in India, mandate that such changes undergo prior review and approval to maintain the product's safety, efficacy, and quality profiles.

The importance of regulating PACs lies in maintaining a delicate balance between encouraging innovation and ensuring stability in pharmaceutical production. The process of submitting and obtaining approval for these changes varies by jurisdiction and depends on the risk classification of the modification. High-impact changes that may influence the clinical profile of a product generally require prior approval from the regulatory authority, while low-risk changes may only require notification or annual reporting. Thus, regulatory systems must be equipped with well-defined frameworks that distinguish between different categories of changes, ensuring proportional oversight while promoting timely implementation.[2]

In India, the need for an efficient post-approval change system has become increasingly critical due to the country's growing status as a global hub for generic medicines and contract manufacturing. As pharmaceutical innovation accelerates, so does the frequency of manufacturing and process-related updates. A robust PAC regulatory mechanism ensures that Indian pharmaceutical manufacturers remain compliant with international quality benchmarks while minimizing disruptions in drug availability.

1.2 Concept and Regulatory Relevance of Post-Approval Changes[3]

The concept of post-approval changes stems from the regulatory principle that a drug's approval is granted based on specific, well-characterized parameters. Any deviation from these parameters—be it in raw materials, manufacturing sites, process controls, formulation, or packaging—has the potential to impact the quality attributes of the finished product. Therefore, regulators view such modifications as "variations" that must be scientifically justified and systematically managed.

Regulatory frameworks classify PACs into different categories depending on the level of potential risk associated with the change. Typically, these include **major changes**, **moderate changes**, and **minor changes**. Major changes are those that may significantly impact the identity, strength, quality, purity, or potency of a product, such as altering the active pharmaceutical ingredient (API) synthesis route or changing the sterilization process of a sterile drug. Moderate changes may include adjustments in excipient ratios or packaging configurations, while minor changes are generally administrative, such as label updates or minor equipment replacements.

Globally, regulatory harmonization efforts, such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (**ICH**) guideline **Q12**—entitled *"Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management"*—have emphasized the importance of a science- and risk-based approach to managing post-approval changes. ICH Q12 provides tools for flexible change management systems that enable manufacturers to implement low-risk changes more efficiently through established reporting categories. This approach minimizes regulatory burden while ensuring product quality through continuous process verification and risk mitigation strategies.[4]

In the Indian regulatory environment, the CDSCO serves as the primary authority overseeing the implementation and approval of post-approval variations. Although India has made notable progress in aligning with global regulatory practices, the framework remains somewhat fragmented, with limited guidance on risk-based categorization and

inconsistent timelines for approval. Many Indian pharmaceutical companies face challenges when navigating the approval process for PACs, particularly when seeking alignment with international markets such as the United States or the European Union.

A transparent and harmonized PAC system is therefore indispensable for India's pharmaceutical industry. It facilitates faster implementation of quality improvements, enhances global competitiveness, and ensures patient safety through lifecycle-based oversight. The present study aims to evaluate the Indian PAC framework comprehensively, assess its congruence with international systems, and propose measures for modernization and harmonization.

1.3 Evolution of Pharmaceutical Regulatory Systems in India

The regulatory control of pharmaceuticals in India has evolved considerably since the enactment of the **Drugs and Cosmetics Act, 1940**, and the **Drugs and Cosmetics Rules, 1945**. Initially focused on ensuring the quality of drugs manufactured and sold within India, the regulatory framework has progressively expanded to encompass the entire product lifecycle—from development and approval to post-marketing surveillance.[5]

The establishment of the **Central Drugs Standard Control Organization (CDSCO)** under the Ministry of Health and Family Welfare marked a significant milestone in India's regulatory evolution. The CDSCO, headed by the Drugs Controller General of India (DCGI), functions as the national regulatory authority responsible for new drug approvals, clinical trial oversight, manufacturing and import licensing, and pharmacovigilance. Over the years, the CDSCO has implemented several regulatory reforms aimed at enhancing transparency, harmonization, and scientific rigor in the approval process.

India's increasing integration into the global pharmaceutical supply chain has necessitated greater alignment with international regulatory norms. The country has adopted several elements of the **Common Technical Document (CTD)** format and **ICH** guidelines, particularly in areas such as stability testing (ICH Q1), impurity limits (ICH Q3), and good manufacturing practices (ICH Q7). However, the domain of post-approval change management still reflects gaps between Indian and international standards.

Historically, post-approval variations in India were managed through amendments to manufacturing licenses or through site inspections conducted by state licensing authorities. However, as the complexity of pharmaceutical manufacturing increased, the need for a centralized, standardized approach became evident.[6] The **New Drugs and Clinical Trials Rules (NDCTR), 2019**, introduced further procedural clarity by streamlining approval categories and timelines, but did not yet establish a fully risk-based framework for PACs.

As India's pharmaceutical exports continue to grow—accounting for over 20% of global generic drug supply—alignment with international post-approval change systems has become essential. International partners, including the USFDA and EMA, increasingly expect regulatory equivalence and timely communication of variations affecting globally distributed products. Hence, India's regulatory evolution must move beyond traditional approval mechanisms and embrace lifecycle-based approaches that facilitate innovation without compromising public health.

1.4 Overview of Indian Post-Approval Change Regulations

The Indian pharmaceutical regulatory framework has gradually evolved to incorporate structured mechanisms for overseeing post-approval changes in drugs. The **Central Drugs Standard Control Organization (CDSCO)**, functioning under the **Directorate General of Health Services (DGHS)** and governed by the **Drugs and Cosmetics Act (1940)** and **Rules (1945)**, serves as the principal authority responsible for approving and regulating such changes. Despite this institutional foundation, India's system for post-approval changes remains less codified compared to those of advanced regulatory jurisdictions.

In India, any modification made after the initial marketing authorization must comply with relevant provisions under the Drugs and Cosmetics Rules and **Schedule M**, which outlines the Good Manufacturing Practices (GMP) for pharmaceuticals. These changes may relate to manufacturing processes, analytical methods, packaging, labeling, or product composition. The **licensing authority**—either the CDSCO for centrally approved products or the **State Licensing Authority (SLA)**[7] for locally approved ones—evaluates the significance of such modifications to determine whether prior approval, notification, or documentation is required.

Typically, post-approval changes in India can be divided into three broad categories:

1. **Major Changes** – These include modifications likely to affect the product's quality, safety, or efficacy, such as changes in the manufacturing site for sterile products, formulation composition, or the route of synthesis of the active ingredient. Major changes generally require **prior approval** from CDSCO before implementation.
2. **Minor Changes** – These encompass modifications that do not significantly impact product performance or safety, such as updates to excipient grades, minor packaging material changes, or administrative label modifications. Minor changes usually require **notification** or **reporting** within a prescribed time frame.
3. **Administrative or Informational Changes** – These include updates in the company's address, product labeling format, or similar non-technical adjustments that may only require record maintenance without formal regulatory submission.[8]

The CDSCO periodically issues guidance through **Notices, Circulars, and Office Orders** to clarify expectations for specific types of post-approval changes. For example, updates to **stability testing data**, **revalidation of manufacturing processes**, and **analytical method validation** must be submitted as part of periodic product dossier updates. The **Drugs Technical Advisory Board (DTAB)** also plays an advisory role in defining the regulatory expectations for such variations.

However, the Indian system currently lacks a formally codified classification framework equivalent to the "Variation Regulation" used by the European Medicines Agency (EMA) or the **21 CFR 314.70** provisions followed by the USFDA. The absence of a detailed categorization matrix for changes often leads to interpretational ambiguities and extended review timelines. Consequently, pharmaceutical companies operating in India face uncertainty regarding documentation requirements and timelines for regulatory clearance, which may impede timely implementation of improvements and affect market supply continuity.

To address these challenges, the CDSCO has increasingly emphasized digital transformation and transparency. The **SUGAM portal**, an online platform for regulatory submissions, has streamlined the filing of post-approval applications, reducing paperwork and enabling better tracking. Yet, despite these advancements, the need remains for a more scientifically robust, risk-based approach aligned[9] with **ICH Q12**, enabling manufacturers to implement low-risk changes efficiently without extensive regulatory delays.

India's post-approval regulatory landscape, therefore, stands at a crossroads—requiring both modernization and harmonization to sustain its global reputation as a reliable producer of high-quality pharmaceuticals.

1.5 International Frameworks: Comparative Overview (ICH, FDA, EMA)

Globally, the regulation of post-approval changes is governed by detailed and harmonized frameworks that emphasize scientific justification, risk assessment, and lifecycle management. Leading regulatory authorities such as the **United States Food and Drug Administration (USFDA)**, the **European Medicines Agency (EMA)**, and the **International Council for Harmonisation (ICH)** have established comprehensive guidelines that serve as international benchmarks.[10]

1.5.1 ICH Framework (ICH Q12)

The ICH guideline **Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management** represents a landmark advancement in harmonizing post-approval change management across regions. Introduced to complement the earlier quality guidelines (Q8–Q11), ICH Q12 focuses on implementing an efficient, science-based system that enables manufacturers to manage product and process changes within an agreed framework with regulators.

ICH Q12 introduces the concept of a **Post-Approval Change Management Protocol (PACMP)** and **Established Conditions (ECs)**. ECs define the key parameters that must remain unchanged to maintain product quality, while changes outside these boundaries require regulatory notification or approval. The PACMP, on the other hand, is a pre-approved plan describing the data and justification a company will provide when proposing specific changes in the future.

By defining these concepts, ICH Q12 enables more predictable and flexible regulatory oversight, reducing the burden of repetitive submissions for routine modifications. The guideline's adoption by

major regulatory bodies—such as the USFDA, EMA, and Japan's PMDA—reflects a global shift toward a lifecycle-based regulatory paradigm.[11]

1.5.2 United States (USFDA)

In the United States, the regulation of post-approval changes for new drugs and abbreviated new drug applications (ANDAs) is governed by **Title 21, Code of Federal Regulations (CFR) §314.70**. The FDA classifies changes into three categories:

1. **Major Changes (Prior Approval Supplement – PAS):** Require FDA approval before distribution of the product made with the change. Examples include changes in formulation, manufacturing site, or sterilization methods.
2. **Moderate Changes (Changes Being Effected – CBE/CBE-30):** May be implemented after FDA notification, typically 30 days prior to distribution. Examples include moderate manufacturing process updates.
3. **Minor Changes (Annual Report):** Reported in the manufacturer's annual update without prior approval.

This system reflects a clear risk-based approach that balances regulatory control with flexibility, enabling manufacturers to make improvements efficiently while maintaining compliance. The FDA also supports lifecycle management principles through initiatives like **Pharmaceutical Quality for the 21st Century**, promoting continuous improvement and modern manufacturing technologies.

1.5.3 European Union (EMA)

The **European Medicines Agency (EMA)**, under the **European Commission's Regulation (EC) No. 1234/2008**, has implemented a well-defined framework for handling post-approval variations. Variations are categorized as:

- **Type IA:** Minor variations with minimal risk, which can be implemented immediately and reported subsequently.
- **Type IB:** Moderate changes requiring prior notification and a short review period.
- **Type II:** Major variations with significant potential impact on product quality, safety, or efficacy, requiring prior approval.
- **Extension Applications:** For substantial modifications that effectively create a new product authorization.[12]

This system, supported by **European Variation Guidelines**, promotes regulatory predictability and enables mutual recognition across EU member states. Moreover, the EMA has established procedures for "Worksharing" and "Grouping," allowing companies to submit a single variation application applicable to multiple products or changes simultaneously.

1.5.4 Comparative Insights

Compared to the USFDA and EMA, India's regulatory approach to post-approval changes is still evolving. While the fundamental principle of prior approval for major changes remains consistent, the absence of a formalized classification structure, clear reporting categories, and defined timelines limits India's efficiency. The implementation of ICH Q12 principles into the Indian regulatory context would help establish a standardized risk-based model, enhancing predictability and reducing administrative burden.

1.6 Role of Lifecycle Management and Continuous Improvement

Pharmaceutical product lifecycle management (PLCM) encompasses all stages from initial development through post-approval modifications, ensuring that the product continues to meet its intended quality, safety, and efficacy standards. Effective lifecycle management is increasingly recognized as a cornerstone of modern regulatory science, promoting proactive quality control rather than reactive compliance.

In the context of post-approval changes, lifecycle management encourages manufacturers to adopt systematic strategies for continuous improvement. As manufacturing technologies evolve—such as through **process analytical technology (PAT)**, **continuous manufacturing**, and **quality by design (QbD)**—the ability to adapt and optimize processes becomes essential.[13] Regulatory systems must therefore provide a framework that allows companies to implement such improvements efficiently without compromising oversight.

ICH Q12 and related guidance documents emphasize the integration of **Quality Risk Management (ICH Q9)** and **Pharmaceutical Quality Systems (ICH**

Q10) as key enablers of lifecycle management. Together, these guidelines form a comprehensive quality framework supporting innovation while ensuring robust regulatory compliance.

In India, lifecycle management practices are gradually gaining traction, driven by the industry's growing engagement with international markets. However, the regulatory infrastructure remains primarily approval-centric, focusing on pre-market evaluation rather than lifecycle-based oversight. Transitioning toward a lifecycle management model would not only align India with global best practices but also strengthen its capacity for sustaining quality across the product's commercial lifespan.

An effective lifecycle management framework thus enables both regulators and manufacturers to anticipate risks, plan controlled changes, and continuously enhance product performance. This paradigm shift from a static to a dynamic regulatory approach represents the future of pharmaceutical regulation and forms the conceptual foundation for evaluating post-approval change requirements in India.[14]

1.7 Importance of Post-Approval Changes in Ensuring Product Quality

The assurance of pharmaceutical quality is a continuous process that extends far beyond the point of marketing authorization. Drugs are dynamic entities whose quality attributes can be influenced by raw-material variability, process drift, evolving technologies, and environmental factors. Consequently, the regulatory concept of **post-approval change (PAC)** is central to maintaining a medicine's integrity throughout its commercial lifecycle.

From a quality-management perspective, post-approval change mechanisms allow manufacturers to implement scientific and technological innovations that enhance product robustness, manufacturing efficiency, and patient safety. Without such flexibility, companies would face stagnation, operating outdated processes that may compromise consistency or sustainability. Thus, regulatory systems must enable improvement while maintaining strict control of risk.[15]

PACs also support **continuous process verification** and **quality by design (QbD)** principles, which rely on feedback loops between manufacturing data and regulatory commitments. For example, analytical method modernization, equipment automation, or process-parameter tightening can reduce variability and enhance reproducibility. Timely approval of these changes ensures that patients consistently receive high-quality medicines conforming to current good-manufacturing-practice (GMP) standards.

Moreover, post-approval changes can address **supply-chain resilience**. Global events—such as raw-material shortages, facility closures, or geopolitical disruptions—often require rapid manufacturing-site transfers or sourcing modifications. A responsive and predictable PAC framework allows such transitions without jeopardizing market availability. In the Indian context, where pharmaceutical exports span over two hundred countries, such agility is indispensable for maintaining uninterrupted global supply.

PACs also play a vital role in **pharmacovigilance and risk mitigation**. When post-marketing surveillance identifies safety signals or stability concerns, manufacturers may need to modify formulations, packaging, or labeling to enhance product safety. A clear regulatory pathway for such changes ensures timely implementation of corrective measures, thereby protecting public health.

Ultimately, an effective post-approval change system embodies the principle of **lifecycle quality assurance**, integrating scientific understanding with regulatory oversight. It empowers manufacturers to maintain compliance with evolving standards while fostering innovation—a balance that is especially critical for a fast-growing pharmaceutical economy like India's.

1.8 Challenges in the Current Indian Regulatory Environment

Despite considerable progress, India's post-approval regulatory system continues to face multiple structural and operational challenges that affect its efficiency and predictability. These issues stem from historical regulatory fragmentation, limited harmonization with international frameworks, and infrastructural constraints that collectively slow the pace of change management.

1.8.1 Regulatory Fragmentation and Lack of Standardized Guidance

One of the most persistent obstacles is the absence of a unified, comprehensive guideline specifically

addressing the categorization and documentation of post-approval changes. Although CDSCO circulars and office orders provide interim direction, they lack the consistency and legal enforceability of codified regulations. Manufacturers often rely on case-by-case correspondence with regulators to interpret requirements, resulting in inconsistent expectations and extended review timelines.[16]

1.8.2 Limited Risk-Based Classification

In contrast to ICH Q12 or the USFDA's 21 CFR 314.70 framework, India has not yet implemented a formal risk-based classification system that differentiates major, moderate, and minor variations through objective criteria. As a result, even low-risk modifications—such as excipient grade substitutions or equipment upgrades—may require lengthy prior-approval processes. This lack of proportional oversight discourages innovation and delays quality improvements.

1.8.3 Lengthy Timelines and Administrative Delays

Another challenge relates to procedural timelines. While CDSCO has introduced the SUGAM online portal to streamline submissions, practical delays remain common due to incomplete documentation, limited reviewer capacity, and inter-departmental coordination gaps. In some instances, approvals for even minor post-approval changes can extend beyond six months, impacting production schedules and export commitments.

1.8.4 Insufficient Transparency and Predictability

Pharmaceutical companies frequently cite the absence of clear communication channels regarding the status of their post-approval applications. Unlike the EMA or USFDA, which publish metrics on average review timelines and provide structured deficiency letters, India's process often lacks publicly available performance indicators. This opacity affects planning, leading to uncertainty in manufacturing operations and supply-chain management.[17]

1.8.5 Resource and Infrastructure Constraints

Effective post-approval regulation requires specialized scientific expertise to assess manufacturing and analytical changes. The CDSCO's human-resource capacity, however, remains limited relative to the volume of applications received annually. Moreover, coordination between the CDSCO and State Licensing Authorities (SLAs) is occasionally inconsistent, creating overlaps or gaps in oversight, especially for multi-site operations and contract manufacturing arrangements.

1.8.6 Global Compliance and Export Challenges

Indian pharmaceutical firms exporting to highly regulated markets must navigate dual regulatory obligations: domestic post-approval requirements and those of importing authorities. Misalignment between these systems can result in duplicate filings, data redundancy, and additional costs. For instance, an ANDA-holder may receive FDA approval for a change but still await CDSCO clearance to implement it locally, creating operational inefficiencies.

Collectively, these challenges underscore the pressing need for regulatory modernization. A harmonized, risk-based system would not only expedite approvals but also enhance India's credibility as a globally compliant manufacturing hub.

1.9 Need for Harmonization and Global Alignment

The globalization of pharmaceutical manufacturing and trade has made regulatory convergence a strategic necessity. As India contributes a substantial portion of the world's generic-drug supply, its regulatory framework must align with international standards to facilitate mutual recognition and efficient global distribution.

1.9.1 Rationale for Regulatory Harmonization

Harmonization of post-approval change requirements reduces duplication of effort and accelerates access to improved medicines worldwide. By aligning with frameworks such as ICH Q12, the USFDA's risk-based classification, and the EMA's variation categories, India can ensure that a single scientific assessment is acceptable across multiple jurisdictions. This approach strengthens international confidence in Indian regulatory decisions and promotes export competitiveness.

1.9.2 Advantages of Global Alignment

Adopting harmonized standards provides multiple benefits:

- **Predictability and Efficiency:** Defined change categories and reporting timelines allow companies to plan manufacturing updates with certainty.
- **Regulatory Reliance:** Alignment enables India to participate in reliance or recognition initiatives, where decisions by trusted authorities can be leveraged to expedite domestic approvals.
- **Quality Culture and Innovation:** A science-based, risk-proportionate system encourages the adoption of modern manufacturing technologies such as continuous manufacturing, process analytical technology (PAT), and real-time release testing (RTRT).[18]
- **Public Health Protection:** Harmonized requirements ensure consistent quality standards, minimizing the risk of substandard medicines entering the supply chain.

1.9.3 Challenges to Harmonization

Despite the clear advantages, implementing harmonization poses its own challenges. Regulatory capacity building, staff training, and legal amendments are prerequisites for adopting ICH-aligned frameworks. Moreover, India's dual-authority structure—where state and central regulators share responsibilities—necessitates coordinated policy execution to prevent jurisdictional conflicts.

1.9.4 Strategic Path Forward

To achieve effective global alignment, India may consider:

1. **Adopting ICH Q12 Principles:** Formally incorporating lifecycle-management concepts, including Post-Approval Change Management Protocols (PACMPs) and Established Conditions (ECs).
2. **Developing a Categorized Variation System:** Establishing clear guidance comparable to EMA's Type IA/IB/II framework.
3. **Digital Transformation:** Expanding the SUGAM platform into a comprehensive electronic-submission and tracking system for all post-approval variations.
4. **Capacity Building:** Enhancing reviewer training and inter-agency collaboration to ensure consistent evaluation.
5. **Stakeholder Engagement:** Conducting regular consultations with industry, academia, and international regulators to refine guidance and build mutual trust.

Through such reforms, India can transition from a predominantly approval-centric model to a **lifecycle-based, globally harmonized regulatory system** that supports innovation and ensures continuous product quality.[19]

1.10 Research Rationale

Pharmaceutical products are dynamic entities whose quality and performance are influenced by a variety of factors, including advancements in manufacturing science, evolving analytical technologies, and changes in regulatory expectations. Once a drug receives marketing authorization, it enters a lifecycle phase that often necessitates modifications in production processes, packaging, labeling, or analytical procedures. These changes are integral to sustaining high-quality standards and maintaining compliance with both domestic and international regulations.

In India, the regulation of post-approval changes (PACs) is a developing domain, characterized by fragmented guidelines and variable interpretation across stakeholders. Unlike the well-established frameworks of agencies such as the USFDA or EMA, India's regulatory system has yet to fully adopt a structured, risk-based approach that categorizes variations according to potential impact on product quality. This lack of standardization can lead to extended approval timelines, uncertainty for manufacturers, and challenges in global regulatory synchronization.

Given India's pivotal role as the world's largest supplier of generic pharmaceuticals, a comprehensive understanding of its PAC framework is crucial. Indian companies are responsible for a significant portion of global medicine exports, and inconsistencies in post-approval processes can affect not only domestic healthcare but also international supply chains. Moreover, global regulatory harmonization efforts—particularly the adoption of ICH Q12—demand that India evolve its systems to align with international best practices.

This research, therefore, seeks to evaluate the existing post-approval change requirements in India, identify key challenges in regulatory implementation, and recommend actionable strategies for modernization. The study aims to bridge the gap between policy intent and operational practice,

contributing to a more predictable and globally harmonized regulatory environment for pharmaceutical lifecycle management.

Scope and Limitations[20]

Scope

The scope of this study encompasses an in-depth examination of the Indian regulatory framework for post-approval changes in pharmaceuticals. It includes evaluation of policies, guidelines, and practices of the **Central Drugs Standard Control Organization (CDSCO)**, **State Licensing Authorities (SLAs)**, and related advisory bodies such as the **Drugs Technical Advisory Board (DTAB)**. The study also integrates comparative perspectives from leading global regulatory agencies—namely the **USFDA**, **EMA**, and **ICH**—to assess India's degree of alignment with international standards.

Key focus areas include:

- Regulatory classification and documentation requirements for different types of post-approval changes.
- Approval timelines, procedural transparency, and reviewer capacity.
- The role of digital submission systems such as the **SUGAM portal**.
- Challenges faced by manufacturers in the implementation of post-approval modifications.
- Opportunities for harmonization and capacity building through risk-based frameworks.

AIM AND OBJECTIVE

Aim:

The primary aim of this study is to evaluate the existing regulatory framework and procedural requirements for post-approval changes (PACs) in pharmaceuticals in India, with a focus on assessing their alignment with international standards, efficiency in implementation, and impact on product quality and market continuity.

Objectives:

1. To analyze the current Indian regulatory guidelines and provisions governing post-approval changes under the CDSCO and related regulatory bodies.
2. To classify and evaluate different categories of post-approval changes, including manufacturing, formulation, packaging, analytical methods, and labeling modifications.
3. To compare Indian post-approval change requirements with international frameworks such as ICH Q12, US FDA, and EMA guidelines.
4. To identify challenges and gaps in the approval process, documentation, and regulatory timelines for implementing PACs in India.
5. To propose recommendations for harmonization, digitalization, and risk-based approaches to improve regulatory efficiency and lifecycle management of pharmaceutical products.

CONCLUSION:

The evaluation of post-approval change (PAC) requirements for pharmaceuticals in India reveals a dynamic but evolving regulatory framework aimed at ensuring consistent product quality, safety, and efficacy throughout a drug's lifecycle. The Central Drugs Standard Control Organization (CDSCO) has made significant progress in establishing structured guidelines; however, the system still faces challenges such as procedural delays, lack of clarity in classification of variations, and limited harmonization with international standards like ICH Q12. Strengthening regulatory convergence, adopting a risk-based approach, and integrating digital submission systems could substantially improve the transparency and efficiency of PAC approvals. Enhanced collaboration between regulators and the pharmaceutical industry, along with clear guidance on documentation and data expectations, will be essential to achieving global best practices. Overall, an optimized post-approval change framework will support continuous improvement, innovation, and sustained patient access to high-quality medicines in India.

ACKNOWLEDGEMENT:

The Authors are thankful to Sura Labs, Dilshukhnagar, Hyderabad for providing the necessary facilities for the research work.

REFERENCES:

1. Central Drugs Standard Control Organization (CDSCO). (2017). *Draft guidance on post-approval changes for pharmaceutical products*. Ministry of Health and Family Welfare, Government of India.
2. Central Drugs Standard Control Organization (CDSCO). (2020). *Guidance for industry on*

submission of applications through SUGAM online portal. New Delhi: CDSCO.
3. Central Drugs Standard Control Organization (CDSCO). (2021). *Regulatory guidelines for filing variations to approved pharmaceutical products in India*. Ministry of Health and Family Welfare.
4. Central Drugs Standard Control Organization (CDSCO). (2023). *National drug regulatory reforms and implementation roadmap for Schedule M (Revised)*. Government of India.
5. Central Drugs Standard Control Organization (CDSCO). (2024). *Pharmaceutical quality systems and risk-based post-approval change management: Draft guidance under revised Schedule M*. Government of India.
6. Department of Pharmaceuticals (DoP). (2023). *National Pharmaceutical Policy 2023: Ensuring access, quality, and affordability*. Ministry of Chemicals and Fertilizers, Government of India.
7. European Commission (EC). (2008). *Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products*. Official Journal of the European Union.
8. European Medicines Agency (EMA). (2019). *Guideline on variations to marketing authorizations: Categorization and procedural guidance*. London: EMA.
9. European Medicines Agency (EMA). (2021). *Post-authorization procedural advice for users of the centralized procedure*. Amsterdam: EMA.
10. Food and Drug Administration (FDA). (2020). *Guidance for industry: Changes to an approved NDA or ANDA*. Silver Spring, MD: U.S. Department of Health and Human Services.
11. Food and Drug Administration (FDA). (2021). *CMC post-approval manufacturing changes for approved drug and biological products*. Center for Drug Evaluation and Research (CDER).
12. Food and Drug Administration (FDA). (2022). *Quality by Design for ANDAs: Questions and answers*. Silver Spring, MD.
13. Food and Drug Administration (FDA). (2023). *Guidance for industry: Quality considerations for continuous manufacturing*. Silver Spring, MD.
14. Government of India. (2024). *The Drugs and Cosmetics (Amendment) Rules, 2024*. Gazette of India, Ministry of Health and Family Welfare.
15. International Council for Harmonisation (ICH). (2009). *ICH Q8(R2): Pharmaceutical development*. Geneva: ICH Secretariat.